Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Aug;106(8):645-655.
doi: 10.1007/s00392-017-1101-6. Epub 2017 Mar 30.

Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial

Mira-Lynn Chavanon  1   2   3 , Simone Inkrot  4 , Christine Zelenak  4 , Elvis Tahirovic  4   5 , Dragana Stanojevic  6 , Svetlana Apostolovic  6 , Aleksandra Sljivic  7   8 , Arsen D Ristic  8   9 , Dragan Matic  8   10 , Goran Loncar  8   11 , Jovan Veskovic  4   5 , Marija Zdravkovic  12 , Mitja Lainscak  13 , Burkert Pieske  4   5 , Christoph Herrmann-Lingen  14   15 , Hans-Dirk Düngen  4   5
Affiliations
Randomized Controlled Trial

Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial

Mira-Lynn Chavanon et al. Clin Res Cardiol. 2017 Aug.

Abstract

Aim: Patient-reported outcomes such as health-related quality of life (HRQoL) are main treatment goals for heart failure (HF) and therefore endpoints in multinational therapy trials. However, little is known about country-specific differences in HRQoL and in treatment-associated HRQoL improvement. The present work sought to examine those questions.

Methods and results: We analysed data from the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD) trial, in which patients from central and south-eastern Europe completed the HRQoL questionnaire SF-36 at baseline and the end of a 12-week beta-blocker up-titration (follow-up). 416 patients from Serbia (mean age 72.21 years, 69% NYHA-class I-II, 27.4% women) and 114 from Germany (mean age 73.64 years, 78.9% NYHA-class I-II, 47.4% women) were included. Controlling for clinical variables, the change in mental HRQoL from baseline to follow-up was modulated by Country: Serbian patients, M baseline = 37.85 vs. M follow-up = 40.99, t(526) = 5.34, p < .001, reported a stronger increase than Germans, M baseline = 37.66 vs. M follow-up = 38.23, t(526) = 0.68, ns. For physical HRQoL, we observed a main effect of Country, M Serbia = 39.28 vs. M Germany = 35.29, t(526) = 4.24, p < .001.

Conclusion: We observed significant differences in HF patients from Germany and Serbia and country-specific differences between Serbian and German patients in mean physical HRQoL. Changes in mental HRQoL were modulated by country. Those results may reflect psychological, sociocultural, aetiological differences or regional differences in phenotype prevalence. More importantly, they suggest that future multinational trials should consider such aspects when designing a trial in order to avoid uncertainties aligned to data interpretation and to improve subsequent treatment optimisation.

Keywords: Beta-blocker; Heart failure; Patient-reported outcomes; Quality of life.

PubMed Disclaimer

References

    1. Eur J Cardiovasc Nurs. 2016 Jun;15(4):241-7 - PubMed
    1. Eur J Heart Fail. 2015 Sep;17(9):893-905 - PubMed
    1. Curr Treat Options Cardiovasc Med. 2013 Aug;15(4):425-36 - PubMed
    1. Br J Health Psychol. 2012 Sep;17 (3):447-62 - PubMed
    1. Age Ageing. 2013 Sep;42(5):626-32 - PubMed

Publication types

MeSH terms

LinkOut - more resources